

Christine M Parseghian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3375835/publications.pdf>

Version: 2024-02-01

13
papers

485
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	1.4	2
2	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	5.9	10
3	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
4	Comprehensive Clinical and Molecular Characterization of KRAS ^{G12C} -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	3.0	31
5	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 98, 106445.	0.8	1
6	KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. <i>Modern Pathology</i> , 2020, 33, 1832-1843.	5.5	18
7	This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. <i>Cancer Cell</i> , 2020, 37, 5-7.	16.8	3
8	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.	7.0	76
9	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	1.2	170
10	Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 402.	7.1	11
11	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	7.0	50
12	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	7.0	70
13	Underreporting of Research Biopsies from Clinical Trials in Oncology. <i>Clinical Cancer Research</i> , 2017, 23, 6450-6457.	7.0	15